Author/Authors :
zheng, kenneth i. wenzhou medical university - mafld research center, the first affiliated hospital - department of hepatology, Wenzhou, China , eslam, mohammed university of sydney - storr liver centre, westmead institute for medical research, westmead hospital, Sydney, Australia , george, jacob university of sydney - storrliver centre, westmead institute for medical research, westmead hospital, Sydney, Australia , zheng, ming-hua university of sydney - storrliver centre, westmead institute for medical research, westmead hospital, Sydney, Australia , zheng, ming-hua wenzhou medical university - institute of hepatology, Wenzhou, china , zheng, ming-hua wenzhou medical university - mafld research center, the first affiliated hospital - department of hepatology, Wenzhou, China , zheng, ming-hua key laboratory of diagnosis and treatment for the development of chronic liver disease in zhejiang province, Wenzhou, China
Abstract :
Editorial: Metabolic-associated fatty liver disease (MAFLD) (1), formerly known as non-alcoholic fatty liver disease, is a major causes of liver cirrhosis (2). MAFLD represents a growing global health and economic burden since approximately one in four people have the disease (3). As a consequence, MAFLD-related cirrhosis is expected to become the leading cause for liver failure and liver cancer, and the major indication for liver transplantation this century (3).
